TD Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

TD Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-40,800	Closed	-$144K	–	1418
2015 Q4	$144K	Sell	40,800 -2,100	-5%	-$8.79K	﹤0.01%	1330
2015 Q3	$216K	Hold	42,900	–	–	﹤0.01%	1286
2015 Q2	$276K	Sell	42,900 -10,239	-19%	-$68.6K	﹤0.01%	1279
2015 Q1	$374K	Sell	53,139 -11,681	-18%	-$84.6K	﹤0.01%	1183
2014 Q4	$499K	Buy	64,820 +9,428	+17%	+$74.6K	﹤0.01%	1097
2014 Q3	$413K	Buy	55,392 +15,892	+40%	+$148K	﹤0.01%	1078
2014 Q2	$382K	Hold	39,500	–	–	﹤0.01%	1101
2014 Q1	$328K	Hold	39,500	–	–	﹤0.01%	1136
2013 Q4	$333K	Hold	39,500	–	–	﹤0.01%	1124
2013 Q3	$315K	Sell	39,500 -700	-2%	-$5.63K	﹤0.01%	1095
2013 Q2	$310K	Buy	+40,200	New	+$313K	﹤0.01%	1036

Other funds holding PDLI

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAM

Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management's PDLI Position: Q1 2016 in Review

TD Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 40,800 shares — an estimated $144K sold.

TD Asset Management first reported a position in PDLI in Q2 2013 and held it in 11 quarters. The position peaked at $499K in Q4 2014. 196 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

TD Asset Management reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
TD Asset Management sold 40,800 PDL BioPharma, Inc. shares in Q1 2016, an estimated $144K.
TD Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 11 quarters.
TD Asset Management's PDL BioPharma, Inc. position peaked at $499K in Q4 2014.
196 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on TD Asset Management's 13F filing for Q1 2016, filed 5 May 2016.